{"nctId":"NCT02826603","briefTitle":"Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis","startDateStruct":{"date":"2016-06-22","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":1114,"armGroups":[{"label":"Secukinumab","type":"EXPERIMENTAL","interventionNames":["Drug: Secukinumab"]},{"label":"Ustekinumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ustekinumab"]}],"interventions":[{"name":"Secukinumab","otherNames":[]},{"name":"Ustekinumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must give a written, signed and dated informed consent\n* Chronic plaque-type psoriasis present for at least 6 months before randomization\n* Moderate to severe plaque psoriasis as defined at randomization by:\n\n  * PASI score of ≥12 and\n  * Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% and\n  * IGA mod 2011 ≥3 (based on a scale of 0-4)\n* Candidate for systemic therapy, defined as having psoriasis inadequately controlled by:\n\n  * Topical treatment (including topical corticosteroids) and/or\n  * Phototherapy and/or\n  * Previous systemic therapy\n\nExclusion Criteria:\n\n* Forms of psoriasis other than plaque psoriasis\n* Drug-induced psoriasis\n* Ongoing use of prohibited treatments\n* Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA, or ustekinumab, or any therapies targeting IL-12 or IL-23\n* Use of any other investigational drugs within 5 half-lives of the investigational treatment before study drug initiation\n* Pregnant or nursing (lactating) women\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12","description":"Number of participants who achieved ≥ 90% reduction in PASI compared to baseline.\n\nLogistic regression analysis of PASI 90 response at Week 12\n\nPASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of body region(head: 0.1, upper limbs: 0.2, trunk: 0.3, lower limbs: 0.4).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"366","spread":null},{"groupId":"OG001","value":"265","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants With IGA Mod 2011 0 or 1 at Week 12","description":"Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"397","spread":null},{"groupId":"OG001","value":"306","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12","description":"Number of participants who achieved ≥ 75% reduction in PASI at Week 12 compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"484","spread":null},{"groupId":"OG001","value":"409","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4","description":"Number of participants who achieved ≥ 75% reduction in PASI at Week 4 compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16","description":"Number of participants who achieved 100% reduction in PASI at Week 16 compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With IGA Mod 2011 0 or 1 at 16 Weeks","description":"Investigator's Global Assessment uses a scale (IGA mod 2011) that rates disease from a score of 0 (clear skin) to 4 (severe disease)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"432","spread":null},{"groupId":"OG001","value":"326","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12","description":"Number of participants who achieved 100% reduction in PASI at Week 12 compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16","description":"Number of participants who achieved ≥ 75% reduction in PASI at Week 16 compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"506","spread":null},{"groupId":"OG001","value":"441","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16","description":"Number of participants who achieved ≥ 90% reduction in PASI at Week 16 compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"423","spread":null},{"groupId":"OG001","value":"299","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 52","description":"Number of participants who achieved ≥ 90% reduction in PASI at Week 52 compared to baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"402","spread":null},{"groupId":"OG001","value":"330","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":29,"n":550},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache","Diarrhoea","Sinusitis"]}}}